Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study.
CONCLUSIONS: Real-life data confirm the efficacy and safety profiles of baricitinib in patients with RA and provide evidence that drug survival is higher in bDMARDs-naïve and seropositive patients.
PMID: 33338001 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
More News: Arthritis | Herpes | Italy Health | Methotrexate | Rheumatoid Arthritis | Rheumatology | Study